Q-omics provides the consensus-scored APP-DT profile across patient tissues and cancer cell-line models. APP-DT expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, APP-DT is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, APP-DT RNA expression shows 11,626 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where APP-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for APP-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes APP-DT survival associations across molecular data types. APP-DT RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible APP-DT RNA expression–survival associations across cancer types. High APP-DT expression shows unfavorable associations in CESC, but favorable associations in KIRC, KIRP, STAD, KICH and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for APP-DT RNA expression.
This table summarizes APP-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for APP-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. APP-DT shows lower tumor expression in KIRC, COAD, THCA, LUAD, LUSC and KICH. The KIRC box plot shows higher APP-DT RNA expression in normal versus tumor tissue (log2 FC = −0.746, t-test p < 0.001).
This table shows molecular features associated with APP-DT in patient tissues and cancer cell lines. In patient samples, APP-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, APP-DT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
